A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid
Primary Purpose
Vocal Fold Palsy, Vocal Cord Paralysis, Vocal Cord Atrophy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Silk Voice
Sponsored by
About this trial
This is an interventional basic science trial for Vocal Fold Palsy focused on measuring silk, vocal fold
Eligibility Criteria
Inclusion Criteria:
To be eligible for enrollment, the Subject must meet the following:
- males or non-pregnant, non-breastfeeding females 21 to 65 years old who are willing to comply with the requirements of the study, including sequential photography, periodic check-ins and retrieval of implanted materials;
- women of childbearing potential using an acceptable form of birth control during the study period and willingness to take a urine pregnancy test at baseline and at the biopsy date;
- sign the Informed Consent form and the Authorization for Use and Release HIPAA form prior to any study-related procedures being performed.
- read and understand English
Exclusion Criteria:
Patients will not enroll in the study if they meet any of the following exclusion criteria:
- a history of allergy or hypersensitivity to injectable hyaluronic acid gel;
- a history of allergy or hypersensitivity to silk;
- a history of severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies
- history of allergies of lidocaine
- a history of susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders.
- currently have a hyaluronic acid device implanted
- the presence of any contraindication to the implant procedures, including use of platelet inhibiting agents or other anticoagulant, in a relevant period before study entry (per the treating investigator's judgment);
- the presence of any condition, which in the opinion of the investigator, that makes the subject unable to complete the study per protocol;
- the presence of known allergies or hypersensitivity reactions to local topical anesthetics or nerve blocking agents (if such products are intended to be used for that subject);
- the presence of cancerous or pre-cancerous lesions in the area to be treated;
- the presence of moderate or severe abnormal rating for firmness or detection of any abnormal structure at the site of injection, such as a scar or lump;
- the current use of immunosuppressive therapy;
- who are using substances that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may, as with any injection, experience increased bruising or bleeding at treatment sites
- a history of connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis or scleroderma;
- participation in any interventional clinical research study within 30 days prior to randomization;
- subjects not likely to stay in the study for up to 13 months because of other commitments, concomitant conditions, or past history;
- subjects anticipated to be unreliable; or subjects who have a concomitant condition that might confuse or confound study treatments or assessments;
- Subject with skin conditions (discoloration, textured, scarring, etc.) in postauricular region that may complicate study evaluation metrics
- Subjects that are not considered to be an appropriate candidate at the discretion of the investigator.
Sites / Locations
- DeNova Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Other
Other
Arm Label
6 month explant
12 month explant
24 month explant
Arm Description
Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
Outcomes
Primary Outcome Measures
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Tissue samples extracted at 6 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Tissue samples extracted at 12 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Tissue samples extracted at 24 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Secondary Outcome Measures
Number of patient and number of reported adverse events reported
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Number of patient and number of reported adverse events reported
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Number of patient and number of reported adverse events reported
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Full Information
NCT ID
NCT04315415
First Posted
February 20, 2020
Last Updated
April 19, 2022
Sponsor
Sofregen Medical, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04315415
Brief Title
A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid
Official Title
A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
January 15, 2020 (Actual)
Primary Completion Date
February 17, 2022 (Actual)
Study Completion Date
April 18, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sofregen Medical, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary study goal is to evaluate the histological characteristic of Silk Voice to evaluate the potential for Silk Voice to deliver long-term results to patients.
Detailed Description
The primary study goal is to evaluate the histological characteristic of Silk Voice at a surrogate implantation site to evaluate the potential for Silk Voice to deliver long-term results to patients. Information obtained from this study will help clinician determine Silk Voice's treatment duration and whether Silk Voice is appropriate for their patient.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vocal Fold Palsy, Vocal Cord Paralysis, Vocal Cord Atrophy
Keywords
silk, vocal fold
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Each subject enrolled will receive implantation of both Silk Voice and control material.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
6 month explant
Arm Type
Other
Arm Description
Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
Arm Title
12 month explant
Arm Type
Other
Arm Description
Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
Arm Title
24 month explant
Arm Type
Other
Arm Description
Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
Intervention Type
Device
Intervention Name(s)
Silk Voice
Intervention Description
Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
Primary Outcome Measure Information:
Title
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Description
Tissue samples extracted at 6 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Time Frame
6 month
Title
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Description
Tissue samples extracted at 12 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Time Frame
12 month
Title
Number of subjects exhibiting histological evidence of newly deposited tissue compared to control implantation.
Description
Tissue samples extracted at 24 -month time points will be qualitatively evaluated for presence of tissue deposition. Changes in tissue composition will be assessed.
Time Frame
24 month
Secondary Outcome Measure Information:
Title
Number of patient and number of reported adverse events reported
Description
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Time Frame
6 month
Title
Number of patient and number of reported adverse events reported
Description
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Time Frame
12 month
Title
Number of patient and number of reported adverse events reported
Description
Localized adverse event associated with material implantation. The number of patients and type of adverse events will be evaluated.
Time Frame
24 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
To be eligible for enrollment, the Subject must meet the following:
males or non-pregnant, non-breastfeeding females 21 to 65 years old who are willing to comply with the requirements of the study, including sequential photography, periodic check-ins and retrieval of implanted materials;
women of childbearing potential using an acceptable form of birth control during the study period and willingness to take a urine pregnancy test at baseline and at the biopsy date;
sign the Informed Consent form and the Authorization for Use and Release HIPAA form prior to any study-related procedures being performed.
read and understand English
Exclusion Criteria:
Patients will not enroll in the study if they meet any of the following exclusion criteria:
a history of allergy or hypersensitivity to injectable hyaluronic acid gel;
a history of allergy or hypersensitivity to silk;
a history of severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies
history of allergies of lidocaine
a history of susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders.
currently have a hyaluronic acid device implanted
the presence of any contraindication to the implant procedures, including use of platelet inhibiting agents or other anticoagulant, in a relevant period before study entry (per the treating investigator's judgment);
the presence of any condition, which in the opinion of the investigator, that makes the subject unable to complete the study per protocol;
the presence of known allergies or hypersensitivity reactions to local topical anesthetics or nerve blocking agents (if such products are intended to be used for that subject);
the presence of cancerous or pre-cancerous lesions in the area to be treated;
the presence of moderate or severe abnormal rating for firmness or detection of any abnormal structure at the site of injection, such as a scar or lump;
the current use of immunosuppressive therapy;
who are using substances that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may, as with any injection, experience increased bruising or bleeding at treatment sites
a history of connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis or scleroderma;
participation in any interventional clinical research study within 30 days prior to randomization;
subjects not likely to stay in the study for up to 13 months because of other commitments, concomitant conditions, or past history;
subjects anticipated to be unreliable; or subjects who have a concomitant condition that might confuse or confound study treatments or assessments;
Subject with skin conditions (discoloration, textured, scarring, etc.) in postauricular region that may complicate study evaluation metrics
Subjects that are not considered to be an appropriate candidate at the discretion of the investigator.
Facility Information:
Facility Name
DeNova Research
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid
We'll reach out to this number within 24 hrs